Compare STEM & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | SERA |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 79.5M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | SERA |
|---|---|---|
| Price | $8.66 | $2.01 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 164.7K | 93.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $81,000.00 |
| Revenue This Year | $3.43 | $875.93 |
| Revenue Next Year | $13.92 | $248.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | 5.19 |
| 52 Week Low | $0.29 | $1.37 |
| 52 Week High | $32.23 | $4.09 |
| Indicator | STEM | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 46.15 |
| Support Level | $0.41 | $1.72 |
| Resistance Level | $10.99 | $3.59 |
| Average True Range (ATR) | 0.76 | 0.19 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 16.31 | 65.45 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.